Showing results (861-870 of 1,190) with videos related to

Sort By:
Pageof 119
American Journal of Hematology|December 24, 2024
Outcomes of Patients With Treated Secondary Acute Myeloid Leukemia: A High-Risk Subtype That Warrants an Independent Prognostic DesignationJayastu Senapati, Hagop M Kantarjian, Fadi G Haddad, et al.
American Journal of Hematology|May 31, 2017
Factors associated with risk of central nervous system relapse in patients with non-core binding factor acute myeloid leukemiaElias Jabbour, Naval Guastad Daver, Nicholas James Short, et al.
American Journal of Hematology|April 12, 2022
Urgent cytoreduction for newly diagnosed acute myeloid leukemia patients allows acquisition of pretreatment genomic data and enrollment on investigational clinical trialsKunhwa Kim, Marina Konopleva, Courtney D DiNardo, et al.
Leukemia Research|August 19, 2003
Phase I and pharmacodynamic study of Triapine, a novel ribonucleotide reductase inhibitor, in patients with advanced leukemiaFrancis J Giles, Paula M Fracasso, Hagop M Kantarjian, et al.
Leukemia & Lymphoma|August 27, 2021
Treatment outcomes for patients with myelodysplastic syndrome/myeloproliferative neoplasms with ring sideroblasts and thrombocytosisRami Komrokji, Megan Melody, Najla Al Ali, et al.
Clinical Nephrology|July 20, 2018
Clostridium difficile infection in patients with chronic kidney disease in MexicoRayo Morfin-Otero, Elvira Garza-Gonzalez, Guillermo Garcia Garcia, et al.
Haematologica|July 22, 2017
Vosaroxin in combination with decitabine in newly diagnosed older patients with acute myeloid leukemia or high-risk myelodysplastic syndromeNaval Daver, Hagop Kantarjian, Guillermo Garcia-Manero, et al.
Blood|April 25, 2013
Phase 2 study of azacytidine plus sorafenib in patients with acute myeloid leukemia and FLT-3 internal tandem duplication mutationFarhad Ravandi, Mona Lisa Alattar, Michael R Grunwald, et al.
The Lancet. Oncology|December 8, 2016
Preleukaemic clonal haemopoiesis and risk of therapy-related myeloid neoplasms: a case-control studyKoichi Takahashi, Feng Wang, Hagop Kantarjian, et al.
The Lancet. Haematology|March 29, 2023
Eprenetapopt combined with venetoclax and azacitidine in TP53-mutated acute myeloid leukaemia: a phase 1, dose-finding and expansion studyGuillermo Garcia-Manero, Aaron D Goldberg, Eric S Winer, et al.
Pageof 119